{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:39:52Z","timestamp":1792809592102,"version":"4.5.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T00:00:00Z","timestamp":1647820800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T00:00:00Z","timestamp":1647820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s00520-022-06982-y","type":"journal-article","created":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T15:03:42Z","timestamp":1647875022000},"page":"7047-7051","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["One changing and challenging scenario: the treatment of cancer patients with bone metastases by bisphosphonates and denosumab, the cost\u2013benefit evaluation of different options, and the risk of medication-related osteonecrosis of the jaw (MRONJ)"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0263-9820","authenticated-orcid":false,"given":"Vittorio","family":"Fusco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Campisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Bedogni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,21]]},"reference":[{"issue":"5","key":"6982_CR1","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1007\/s00520-020-05882-3","volume":"29","author":"A Srivastava","year":"2021","unstructured":"Srivastava A, Nogueras Gonzalez GM, Geng Y, Won AM, Cabanillas ME, Naing A, Myers JN, Li Y, Chambers MS (2021) Prevalence of medication related osteonecrosis of the jaw in patients treated with sequential antiresorptive drugs: systematic review and meta-analysis. Support Care Cancer 29(5):2305\u20132317. https:\/\/doi.org\/10.1007\/s00520-020-05882-3","journal-title":"Support Care Cancer"},{"issue":"6","key":"6982_CR2","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1007\/s00520-020-05855-6","volume":"29","author":"R Querrer","year":"2021","unstructured":"Querrer R, Ferrare N, Melo N, Stefani CM, Dos Reis PED, Mesquita CRM, Borges GA, Leite AF, Figueiredo PT (2021) Differences between bisphosphonate-related and denosumab-related osteonecrosis of the jaws: a systematic review. Support Care Cancer 29(6):2811\u20132820. https:\/\/doi.org\/10.1007\/s00520-020-05855-6","journal-title":"Support Care Cancer"},{"issue":"8","key":"6982_CR3","doi-asserted-by":"publisher","first-page":"4763","DOI":"10.1007\/s00520-021-06018-x","volume":"29","author":"H Ikesue","year":"2021","unstructured":"Ikesue H, Mouri M, Tomita H, Hirabatake M, Ikemura M, Muroi N, Yamamoto S, Takenobu T, Tomii K, Kawakita M, Katoh H, Ishikawa T, Yasui H, Hashida T (2021) Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases. Support Care Cancer 29(8):4763\u20134772. https:\/\/doi.org\/10.1007\/s00520-021-06018-x","journal-title":"Support Care Cancer"},{"issue":"8","key":"6982_CR4","doi-asserted-by":"publisher","first-page":"4185","DOI":"10.1007\/s00520-021-06100-4","volume":"29","author":"M Rossi","year":"2021","unstructured":"Rossi M, Gambino A, Cabras M, Alessio M, Fusco V (2021) Persistence, compliance, discontinuation rates and switch rates in denosumab and bisphosphonate treatment of bone metastases in cancer patients: reasons of switch, osteonecrosis of the jaw (ONJ) and other critical points. Support Care Cancer 29(8):4185\u20134186. https:\/\/doi.org\/10.1007\/s00520-021-06100-4","journal-title":"Support Care Cancer"},{"issue":"12","key":"6982_CR5","doi-asserted-by":"publisher","first-page":"7687","DOI":"10.1007\/s00520-021-06362-y","volume":"29","author":"R Jardim Caldas","year":"2021","unstructured":"Jardim Caldas R, Sp\u00edndola Antunes H, de Oliveira RodiniPegoraro C, Ribeiro Guedes F, da Silva Santos PS (2021) Oral health condition in cancer patients under bisphosphonate therapy. Support Care Cancer 29(12):7687\u20137694. https:\/\/doi.org\/10.1007\/s00520-021-06362-y","journal-title":"Support Care Cancer"},{"issue":"12","key":"6982_CR6","doi-asserted-by":"publisher","first-page":"7895","DOI":"10.1007\/s00520-021-06361-z","volume":"29","author":"L Schubert","year":"2021","unstructured":"Schubert L, Russmueller G, Lagler H, Tobudic S, Heindel E, Kundi M, Steininger C (2021) Bone turnover markers can predict healing time in medication-related osteonecrosis of the jaw. Support Care Cancer 29(12):7895\u20137902. https:\/\/doi.org\/10.1007\/s00520-021-06361-z","journal-title":"Support Care Cancer"},{"key":"6982_CR7","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1007\/s00520-021-06634-7","volume":"4","author":"H Ikesue","year":"2021","unstructured":"Ikesue H, Doi K, Morimoto M, Hirabatake M, Muroi N, Yamamoto S, Takenobu T, Hashida T (2021) Risk evaluation of denosumab and zoledronic acid for medication-related osteonecrosis of the jaw in patients with bone metastases: a propensity score-matched analysis. Support Care Cancer 4:524. https:\/\/doi.org\/10.1007\/s00520-021-06634-7 (Online ahead of print)","journal-title":"Support Care Cancer"},{"issue":"8","key":"6982_CR8","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1200\/JOP.18.00444","volume":"14","author":"S Leng","year":"2018","unstructured":"Leng S, Lentzsch S (2018) Bone-modifying agents: complicated to use. J Oncol Pract 14(8):469\u2013470. https:\/\/doi.org\/10.1200\/JOP.18.00444","journal-title":"J Oncol Pract"},{"issue":"8","key":"6982_CR9","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1200\/JOP.18.00236","volume":"14","author":"E Campagnaro","year":"2018","unstructured":"Campagnaro E, Reimers MA, Qin A, Alva AS, Schneider BJ, Van Poznak CH (2018) Use of bone-modifying agents in myeloma and bone metastases: how recent dosing interval studies have affected our practice. J Oncol Pract 14(8):457\u2013464. https:\/\/doi.org\/10.1200\/JOP.18.00236","journal-title":"J Oncol Pract"},{"issue":"1","key":"6982_CR10","doi-asserted-by":"publisher","first-page":"152","DOI":"10.3390\/jcm10010152","volume":"10","author":"AD Anastasilakis","year":"2021","unstructured":"Anastasilakis AD, Makras P, Yavropoulou MP, Tabacco G, Naciu AM, Palermo A (2021) Denosumab discontinuation and the rebound phenomenon: a narrative review. J Clin Med 10(1):152. https:\/\/doi.org\/10.3390\/jcm10010152","journal-title":"J Clin Med"},{"key":"6982_CR11","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.critrevonc.2019.04.020","volume":"139","author":"A Hussain","year":"2019","unstructured":"Hussain A, Lee RJ, Graff JN, Halabi S (2019) The evolution and understanding of skeletal complication endpoints in clinical trials of tumors with metastasis to the bone. Crit Rev Oncol Hematol 139:108\u2013116. https:\/\/doi.org\/10.1016\/j.critrevonc.2019.04.020","journal-title":"Crit Rev Oncol Hematol"},{"issue":"25","key":"6982_CR12","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1200\/JCO.19.01186","volume":"37","author":"N Yarom","year":"2019","unstructured":"Yarom N, Shapiro CL, Peterson DE, Van Poznak CH, Bohlke K, Ruggiero SL, Migliorati CA, Khan A, Morrison A, Anderson H, Murphy BA, Alston-Johnson D, Mendes RA, Beadle BM, Jensen SB, Saunders DP (2019) Medication-related osteonecrosis of the jaw: MASCC\/ISOO\/ASCO Clinical Practice Guideline. J Clin Oncol 37(25):2270\u20132290. https:\/\/doi.org\/10.1200\/JCO.19.01186","journal-title":"J Clin Oncol"},{"issue":"7","key":"6982_CR13","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1111\/odi.13160","volume":"25","author":"M Schiodt","year":"2019","unstructured":"Schiodt M, Otto S, Fedele S, Bedogni A, Nicolatou-Galitis O, Guggenberger R, Herlofson BB, Ristow O, Kofod T (2019) Workshop of European task force on medication-related osteonecrosis of the jaw\u2014current challenges. Oral Dis 25(7):1815\u20131821. https:\/\/doi.org\/10.1111\/odi.13160","journal-title":"Oral Dis"},{"issue":"3","key":"6982_CR14","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1200\/JOP.19.00645","volume":"16","author":"V Fusco","year":"2020","unstructured":"Fusco V, Santini D, Campisi G, Bertoldo F, Lanzetta G, Ibrahim T, Bertetto O, Numico G, Addeo A, Berruti A, Bettini G, Saia G, Bedogni A (2020) Comment on Medication-related osteonecrosis of the jaw: MASCC\/ISOO\/ASCO Clinical Practice Guideline Summary. JCO Oncol Pract 16(3):142\u2013145. https:\/\/doi.org\/10.1200\/JOP.19.00645","journal-title":"JCO Oncol Pract"},{"issue":"35","key":"6982_CR15","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.1200\/JCO.2017.75.4614","volume":"35","author":"C Van Poznak","year":"2017","unstructured":"Van Poznak C, Somerfield MR, Barlow WE, Biermann JS, Bosserman LD, Clemons MJ, Dhesy-Thind SK, Dillmon MS, Eisen A, Frank ES, Jagsi R, Jimenez R, Theriault RL, Vandenberg TA, Yee GC, Moy B (2017) Role of bone-modifying agents in metastatic breast cancer: an American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update. J Clin Oncol 35(35):3978\u20133986. https:\/\/doi.org\/10.1200\/JCO.2017.75.4614","journal-title":"J Clin Oncol"},{"issue":"15","key":"6982_CR16","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1200\/JCO.19.03148","volume":"38","author":"PJ Saylor","year":"2020","unstructured":"Saylor PJ, Rumble RB, Tagawa S, Eastham JA, Finelli A, Reddy PS, Kungel TM, Nissenberg MG, Michalski JM (2020) Bone health and bone-targeted therapies for prostate cancer: ASCO Endorsement of a Cancer Care Ontario Guideline. J Clin Oncol 38(15):1736\u20131743. https:\/\/doi.org\/10.1200\/JCO.19.03148","journal-title":"J Clin Oncol"},{"issue":"12","key":"6982_CR17","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1016\/j.annonc.2020.07.019","volume":"31","author":"R Coleman","year":"2020","unstructured":"Coleman R, Hadji P, Body JJ, Santini D, Chow E, Terpos E, Oudard S, Bruland \u00d8, Flamen P, Kurth A, Van Poznak C, Aapro M, Jordan K, ESMO Guidelines Committee (2020) Bone health in cancer: ESMO Clinical Practice Guidelines. Ann Oncol 31(12):1650\u20131663. https:\/\/doi.org\/10.1016\/j.annonc.2020.07.019","journal-title":"Ann Oncol"},{"issue":"2","key":"6982_CR18","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1080\/17843286.2017.1348001","volume":"73","author":"T Loyson","year":"2018","unstructured":"Loyson T, Van Cann T, Sch\u00f6ffski P, Clement PM, Bechter O, Spriet I, Coropciuc R, Politis C, Vandeweyer RO, Schoenaers J, Dumez H, Berteloot P, Neven P, Nackaerts K, Woei-A-Jin FJSH, Punie K, Wildiers H, Beuselinck B (2018) Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab. Acta Clin Belg 73(2):100\u2013109. https:\/\/doi.org\/10.1080\/17843286.2017.1348001","journal-title":"Acta Clin Belg"},{"issue":"6","key":"6982_CR19","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1007\/s00280-021-04262-w","volume":"87","author":"H Ikesue","year":"2021","unstructured":"Ikesue H, Doi K, Morimoto M, Hirabatake M, Muroi N, Yamamoto S, Takenobu T, Hashida T (2021) Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases. Cancer Chemother Pharmacol 87(6):871\u2013877. https:\/\/doi.org\/10.1007\/s00280-021-04262-w","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"6982_CR20","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1007\/s00520-017-3903-5","volume":"26","author":"T van Cann","year":"2018","unstructured":"van Cann T, Loyson T, Verbiest A, Clement PM, Bechter O, Willems L, Spriet I, Coropciuc R, Politis C, Vandeweyer RO, Schoenaers J, Debruyne PR, Dumez H, Berteloot P, Neven P, Nackaerts K, Woei-A-Jin FJSH, Punie K, Wildiers H, Beuselinck B (2018) Incidence of medication-related osteonecrosis of the jaw in patients treated with both bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors. Support Care Cancer 26(3):869\u2013878. https:\/\/doi.org\/10.1007\/s00520-017-3903-5","journal-title":"Support Care Cancer"},{"key":"6982_CR21","doi-asserted-by":"crossref","unstructured":"Cabras M, Gambino A, Conrotto D,Garrone M, Fasciolo A, Basano L, Gilardetti M, Galassi C, Fusco V. (2021) Survival of metastatic cancer patients and myeloma patients after diagnosis of Osteonecrosis of Jaws (ONJ). Potential impact on ONJ treatment strategies. https:\/\/www.qeios.com\/read\/IKLIWH","DOI":"10.32388\/IKLIWH"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-022-06982-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-022-06982-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-022-06982-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T03:08:11Z","timestamp":1744168091000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-022-06982-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,21]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["6982"],"URL":"https:\/\/doi.org\/10.1007\/s00520-022-06982-y","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,21]]},"assertion":[{"value":"27 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Vittorio Fusco received honoraria as a consultant by Merck; Giuseppina Campisi received honoraria for speakers\u2019 bureau by Qb group; Alberto Bedogni received honoraria as consultant by Amgen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}